Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 323 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR Will Ponsegromab Be a Game Changer for Cancer Cachexia? October 17, 2024 10 Ways to Brave Cancer Treatment: Tips from a Survivor September 27, 2022 GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... October 1, 2020 Do Cancer Survivors Have To Be Positive All the Time? Letting... November 10, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Tegafur Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... TRACERx EVO, a new programme to transform lung cancer research
